Search CTL/CD8+ T-Cell Epitope Database

Found 1 matching record:

Displaying record number 1649

Download this epitope record as JSON.

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location	p17(77-85)
Epitope	SLFNTVATL	Epitope Alignment
		Show epitope variants
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 exposed seronegative, HIV-1 infection
Experimental methods
Keywords	subtype comparisons, HIV exposed persistently seronegative (HEPS), immunodominance

Notes

• Variants SL(F/Y)NTVATL are A/B clade specific.
• ELISPOT was used to study CTL responses to a panel of 54 predefined HIV-1 epitopes in 91 HIV-1-exposed, persistently seronegative (HEPS) and 87 HIV-1-infected female Nairobi sex workers.
• Responses in HEPS women tended to be lower, and focused on different epitopes with HLA presenting molecules that have previously been associated with reduced risk of infection, and there was a shift in the response in the HEPS women upon late seroconversion to epitopes recognized by the HIV-1 infected women.
• 43/91 HEPS women had CD8+ responses and detection of HIV-1-specific CTL in HEPS women increased with the duration of viral exposure.
• Among HLA-A2 women, 1/10 HEPS and 22/26 HIV-1 infected women recognized this epitope, likelihood ratio 18.3, p value < 0.003, and ILK(D/E)PVHGV tended to be more reactive in HEPS women, SL(F/Y)NTVATL in infected women.
• The dominant response to this HLA allele was to this epitope in the 1/10 HEPS case and in 18 of the 22/26 HIV-1 infected women that responded.
• Differences in epitope specificity were only seen for responses restricted by class I HLA alleles A2, A24, A*6802, B14, and B18, previously shown to be associated with resistance to HIV-1 in this cohort.
• Subject ML 1250 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, which switched to SL(F/Y)NTVATL post-seroconversion.
• Subjects ML 1575 and ML 1592 had no response to SL(F/Y)NTVATL prior to seroconversion, but made responses post-seroconversion.
• Subject ML 1760 had an A2 response to ILK(D/E)PVHGV prior to seroconversion, and gained responses to epitopes A2 SL(F/Y)NTVATL and B27 KRWII(L/M)GLNK post-seroconversion.

References

Kaul2001a R. Kaul, T. Dong, F. A. Plummer, J. Kimani, T. Rostron, P. Kiama, E. Njagi, E. Irungu, B. Farah, J. Oyugi, R. Chakraborty, K. S. MacDonald, J. J. Bwayo, A. McMichael, and S. L. Rowland-Jones. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest., 107(10):1303-10, May 2001. URL: http://www.jci.org/cgi/content/full/107/10/1303. PubMed ID: 11375420. Show all entries for this paper.